Magna International Inc. Common Stock vs Regeneron Pharmaceuticals Inc — how do they compare? Magna International Inc. Common Stock trades at $64.08 (market cap $17.04B), while Regeneron Pharmaceuticals Inc trades at $744.35 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4.5× Magna International Inc. Common Stock's market cap, and Magna International Inc. Common Stock pays the higher dividend (3.1%). Which is the better fit depends on your goals — on Pluang, investors hold Magna International Inc. Common Stock for 0 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| MGA | REGN | |
|---|---|---|
Market Cap | $17.04B | $76.14B |
Volume | 1,523,784 | 500,239 |
Sector | Consumer Cyclical | Health |
52-Week High | $73.05 | $852.03 |
52-Week Low | $43.54 | $557.73 |
Typical Hold Time | 0 Days | 107 Days |
Enterprise Value | $22.08B | $70.85B |
Dividend Yield | 3.1% | 0.51% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Magna International Inc. is a Canada-based automotive supplier that designs, engineers, and manufactures vehicle systems and components, including body and chassis structures, seating, powertrain, and electronics, and provides complete-vehicle engineering and contract assembly, with manufacturing operations in 28 countries.
Read more on MGA →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →